Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
401.08
+0.92 (+0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
May 02, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce First Quarter 2022 Financial Results on May 5
April 21, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
April 20, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Inc. (VRTX) Climbs to Annual-High Share Price
March 28, 2022
Via
Investor Brand Network
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
March 31, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Inc. (VRTX) Climbs to Annual-High Share Price
March 28, 2022
Via
Investor Brand Network
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
March 26, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
March 22, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
January 26, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
January 18, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
January 11, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
January 04, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
December 01, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
November 19, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
November 12, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Third-Quarter 2021 Financial Results
November 02, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
October 26, 2021
From
Mammoth Biosciences
Via
Business Wire
Vertex to Announce Third-Quarter 2021 Financial Results on November 2
October 22, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
October 19, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
October 18, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
September 13, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis
August 26, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
August 04, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Second-Quarter 2021 Financial Results
July 29, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
July 28, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
July 19, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce Second-Quarter 2021 Financial Results on July 29
July 16, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients
June 28, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis
June 25, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
June 18, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.